Abstracts tagged "mechanisms"

Abstract Number: 437 • 2018 ACR/ARHP Annual Meeting
Does Reduction in Mechanical Knee Joint Loading Explain the Beneficial Effects of Weight Loss in Overweight or Obese Patients with Knee Osteoarthritis?
Dennis Ang¹, Daniel Beavers² and Stephen P. Messier³, ¹Wake Forest University School of Medicine, Winston-Salem, NC, ²Biostatistical Science, Wake Forest School of Medicine, WINSTON SALEM, NC, ³Department of Health and Exerc, Wake Forest University, Winston-Salem, NC
Background/Purpose: Knee osteoarthritis (KOA) is traditionally considered a local joint pathology. The effect of obesity on the pathogenesis of KOA is predominantly attributed to increase…
Abstract Number: 452 • 2018 ACR/ARHP Annual Meeting
Features of Peripheral and Central Sensitization and Neuropathic Pain Are Seen in Both Osteoarthritis and Rheumatoid Arthritis
Jacquelin R. Chua¹, Shingo Ishihara², Mariam Riad¹, Isabel Castrejón¹, Rachel E. Miller³, Anne-Marie Malfait⁴, Joel A. Block¹, Theodore Pincus¹ and Najia Shakoor¹, ¹Division of Rheumatology, Rush University Medical Center, Chicago, IL, ²Internal Medicine, Rush University Medical Center, Chicago, IL, ³Biochemistry, Rush University Medical Center, Chicago, IL, ⁴Biochemistry & Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: OA and RA are among the most common chronic painful rheumatic diseases. Appreciation of the role of pain sensitization in OA has revolutionized the…
Abstract Number: 628 • 2018 ACR/ARHP Annual Meeting
Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database
Elliot Hepworth¹, Mohammad Movahedi², Emmanouil Rampakakis³, Reza Mirza¹, Arthur Lau⁴, Angela Cesta⁵, Janet E. Pope⁶ and Claire Bombardier⁷, ¹Department of Internal Medicine, McMaster University, Hamilton, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴50 Charlton Avenue East, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: For patients with Rheumatoid Arthritis (RA) who do not achieve adequate clinical response with combined conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), the next…
Abstract Number: 1109 • 2018 ACR/ARHP Annual Meeting
Gene Expressions of TMEM176A and TMEM176B Were Prominent at the Stage of Subclinical Pulmonary Vascular Disease in Systemic Sclerosis
Yoshinobu Koyama¹, Soichiro Fuke², Takashi Ohno³, Yoshiharu Sato⁴ and Toshie Higuchi¹, ¹Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan, ²Department of Cardiology, Japan Red Cross Okayama Hospital, Okayama, Japan, ³Management of medical safety, Okayama University Hospital, Okayama, Japan, ⁴DNA Chip Research Inc, Tokyo, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) is prominent as a vascular involvement of systemic sclerosis (SSc), which remains a leading cause of death in spite of…
Abstract Number: 2589 • 2017 ACR/ARHP Annual Meeting
Functional and Mechanistic Characterization of Anifrolumab, a Fully Human Monoclonal Antibody Targeting the Interferon Alpha Receptor 1 for the Treatment of SLE
Gary P. Sims¹, Jeffrey Riggs², Richard Hanna¹, Bhargavi Rajan³, Jodi Karnell¹, Kamelia Zerrouki¹, Divya Sagar¹, Inna Vainshtein³, Erika Farmer⁴, Meina Liang³, Miguel A. Sanjuan¹ and Roland Kolbeck¹, ¹Respiratory, Inflammation and Autoimmunity (RIA), MedImmune, LLC, Gaithersburg, MD, ²Respiratory, Inflammation and Autoimmunity (RIA), MedImmune LLC, Gaithersburg, MD, ³MedImmune, LLC, Mountain View, CA, ⁴Analytical Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Increased type I interferon (IFN) activity is associated with the pathogenesis of SLE. Anifrolumab, a fully human immunoglobulin (Ig) G1 κ monoclonal antibody in clinical…
Abstract Number: 1989 • 2016 ACR/ARHP Annual Meeting
Mechanism of STAT3 Gain-of-Function in a Patient with JIA
Tiphanie P. Vogel^1,2, Nermina Saucier³, Molly P. Keppel³ and Megan A. Cooper^3,4, ¹Pediatrics/Rheumatology, Washington University in St. Louis, St. Louis, MO, ²Internal Medicine/Rheumatology, Washington University in St. Louis, Saint Louis, MO, ³Pediatrics/Rheumatology, Washington University in St. Louis, Saint Louis, MO, ⁴Pathology and Immunology, Washington University in St. Louis, Saint Louis, MO
Background/Purpose: The transcription factor signal transducer and activator of transcription 3 (STAT3) mediates cytokine-induced changes in gene expression. STAT3 is classically activated by phosphorylation followed…
Abstract Number: 1805 • 2015 ACR/ARHP Annual Meeting
Functional and Mechanistic Characterization of Anifrolumab, a Fully Human, Anti-IFNAR1 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Jeffrey Riggs¹, Brian Naiman², Jing Zhang¹, Yan Xu¹, Inna Vainshtein³, Carl Hay¹, Kevin Schifferli¹, Pina Cardarelli⁴, Meina Liang⁵, Lorin Roskos⁶, Jane Connor⁷, Roland Kolbeck⁸, Anthony Coyle⁹ and Michael Fung¹, ¹MedImmune LLC, Gaithersburg, MD, ²Research, MedImmune LLC, Gaithersburg, MD, ³MedImmune LLC, Hayward, CA, ⁴Medarex, Sunnyvale, CA, ⁵PKPD&Bioanalysis, MedImmune LLC, Hayward, CA, ⁶MedImmune LLC, Mountain View, CA, ⁷Respiratory, Inflammation and Autoimmunity (RIA), MedImmune LLC, Gaithersburg, MD, ⁸Department of Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, ⁹Centers for Therapeutic Innovation, Pfizer, Inc. (formerly MedImmune LLC, Gaithersburg, MD, USA), Cambridge, MA
Background/Purpose: Increased type I interferon (IFN) activities are associated with the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab, a fully human, IgG1 κ monoclonal antibody…
Abstract Number: 2605 • 2015 ACR/ARHP Annual Meeting
14-3-3η Positive Status and Higher Titres Are Associated with More Severe RA
Shintaro Hirata¹, Kentaro Hanami², Anthony Marotta³ and Yoshiya Tanaka⁴, ¹The First Department of Internal Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Augurex Life Sciences Corp., Vancouver, BC, Canada, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Serum 14-3-3η is an RA diagnostic marker that is associated with radiographic progression risk. In vitro studies describe 14-3-3η's potent, dose-dependent up-regulation of factors…
Abstract Number: 1972 • 2014 ACR/ARHP Annual Meeting
Analysis of Anakinra in Primary Human Cell Systems Reveals an in Vitro Signature for Skin-Related Side Effects
Ellen L. Berg, Alison O'Mahony and Mark A Polokoff, BioSeek, South San Francisco, CA
Background/Purpose The therapeutic options for treatment of rheumatic diseases have grown and now include a variety of inflammatory pathway inhibitors, with diverse mechanisms, but having…
Abstract Number: 2567 • 2013 ACR/ARHP Annual Meeting
Cadherin-11 Regulates Pulmonary Fibrosis In Bleomycin-Induced Lung Injury
Mesias Pedroza, Anuh T. George and Sandeep K. Agarwal, Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX
Background/Purpose: Pulmonary fibrosis (PF) is the leading cause of death in systemic sclerosis. Pathologically, PF is characterized by an aberrant wound healing repair mechanism leading…
Abstract Number: 2218 • 2013 ACR/ARHP Annual Meeting
Gingival Stem Cells Suppress Osteoclast Formation and Bone Erosion In CIA Through CD39 Signal
Song Guo Zheng¹, Jian Gu², Maogeng Chen¹ and Yi Shen³, ¹Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, ²Medcine, University of Southern California Keck School of Medicine, Los Angeles, CA, ³Medicine, Shanghai East Hospital at Tongji University, Shanghai, China
Background/Purpose: We recently have reported that human-derived gingival mesenchymal stem cells (GMSC) have strong capacity to suppress immune responses and T cell-mediated collagen-induced arthritis, however,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].